NEW YORK, NY / ACCESSWIRE / February 26, 2017 / Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Agile Therapeutics, Inc. ("Agile" or the "Company") (AGRX) of the March 7, 2017 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers.
The lawsuit has been filed in the U.S. District Court for the District of New Jersey on behalf of all those who purchased Agile stock or options between March 9, 2016 and January 3, 2017 (the "Class Period"). The case, PENG v. AGILE THERAPEUTICS, INC. et al, No. 17-cv-00119, was filed on January 6, 2017, and has been assigned to Judge Lois H. Goodman.
The lawsuit focuses on whether the Company and its executives violated federal securities laws by failing to disclose the lack of efficacy of the Company's contraceptive patch, Twirla, and by misrepresenting Twirla's potential to obtain U.S. Food and Drug Administration ("FDA") approval.
Specifically, during aftermarket hours on January 3, 2017, Agile revealed data from its Phase 3 SECURE study evaluating Twirla. Among the results, the Company stated that 51.4% of subjects had withdrawn from the study and that 1.7% of test subjects suffered "serious adverse events." After the announcement, Agile's share price fell from $5.00 per share on January 3, 2017 to a closing price of $2.63 on January 4, 2017 - a $2.37 or a 47.40% drop.
Request more information now by clicking here: www.faruqilaw.com/AGRX. There is no cost or obligation to you.
If you invested in Agile stock or options between March 9, 2016 and January 3, 2017 and would like to discuss your legal rights, visit www.faruqilaw.com/AGRX. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to firstname.lastname@example.org. Faruqi & Faruqi, LLP also encourages anyone with information regarding Agile's conduct to contact the firm, including whistleblowers, former employees, shareholders, and others.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class that is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
Telephone: (877) 247-4292 or (212) 983-9330
SOURCE: Faruqi & Faruqi, LLP